uz
Feedback
Respiratory Module | MW

Respiratory Module | MW

Kanalga Telegram’da o‘tish

Respiratory Module Data لمشاركة القناة https://t.me/Resp_Module البوت للوصول السريع للداتا https://t.me/Medicine_way_bot?start=mb1029 القناة الرئيسية - @Medicine_Way2

Ko'proq ko'rsatish

📈 Telegram kanali Respiratory Module | MW analitikasi

Respiratory Module | MW (@resp_module) Arab til segmentidagi kanali faol ishtirokchi. Hozirda hamjamiyat 17 196 obunachidan iborat bo'lib, Tibbiyot toifasida 1 365-o'rinni va Saudiya Arabistoni mintaqasida 4 333-o'rinni egallagan.

📊 Auditoriya ko‘rsatkichlari va dinamika

невідомо sanasidan buyon loyiha tez o‘sib, 17 196 obunachiga ega bo‘ldi.

19 Iyun, 2026 dagi oxirgi ma’lumotlarga ko‘ra kanal barqaror faollikka ega. Oxirgi 30 kunda obunachilar soni 123 ga, so‘nggi 24 soatda esa 3 ga o‘zgardi va umumiy qamrov yuqori darajada qolmoqda.

  • Tasdiqlash holati: Tasdiqlanmagan
  • Jalb etish (ER): Auditoriya o‘rtacha 4.00% darajada jalb etiladi. Nashrdan keyingi dastlabki 24 soatda kontent odatda umumiy obunachilar sonining N/A% ini tashkil etuvchi reaksiyalarni to‘playdi.
  • Post qamrovi: Har bir post o‘rtacha 0 marta ko‘riladi; birinchi sutkada odatda 0 ta ko‘rish yig‘iladi.
  • Reaksiyalar va o‘zaro ta’sir: Auditoriya faol: har bir postga o‘rtacha 0 ta reaksiya keladi.
  • Tematik yo‘nalishlar: Kontent مَادَّة, مَجمَع, كِتَاب, مَدِيُّول, مَدِيُّل kabi asosiy mavzularga jamlangan.

📝 Tavsif va kontent siyosati

Muallif resursni shaxsiy fikrni ifoda etish maydoni sifatida ta’riflaydi:
Respiratory Module Data لمشاركة القناة https://t.me/Resp_Module البوت للوصول السريع للداتا https://t.me/Medicine_way_bot?start=mb1029 القناة الرئيسية - @Medicine_Way2

Yuqori yangilanish chastotasi (oxirgi ma’lumot 20 Iyun, 2026 da olingan) sababli kanal doimo dolzarb va katta qamrovli bo‘lib qoladi. Analitika auditoriya kontent bilan faol hamkorlik qilishini, uni Tibbiyot toifasidagi muhim ta’sir nuqtasiga aylantirishini ko‘rsatadi.

17 196
Obunachilar
+324 soatlar
+177 kunlar
+12330 kunlar
Postlar arxiv
39 - L7 , Diseases of pulmonary vasculatures , Patho.mp4 Quality : 🎬 480p

38 - L6 , Restrictive lung disease (Atlectasis) and Acute adult respiratory distress syndrome (ARDS)patho.mp4 Quality : 🎬 480p

37 - L5, bronchiectasis , Patho.mp4 Quality : 🎬 480p

36 - Tut, Lung volumes and capacities, physio.mp4 Quality : 🎬 480p

35 - L3 , Antifungal and antiviral drugs , Pharma.mp4 Quality : 🎬 480p

34 - L6 , Viral respiratory tract infections 2 , Micro.mp4 Quality : 🎬 480p

33 - L7, Fungal infections, Micro.mp4 Quality : 🎬 480p

32 - L5 viral respiratory tract infection 1 , Micro.mp4 Quality : 🎬 480p

31 - L2 , Antituberculous drugs , Pharma.mp4 Quality : 🎬 480p

30 - L4 , Mycobacterium tuberculosis , Micro.mp4 Quality : 🎬 480p

29 - Tutorial 2 , Lung surfactant & L⧸S ratio binding of hemoglobin to oxygen , Bio.mp4 Quality : 🎬 480p

28 - L3 part 2, Lower respiratory tract infections, micro.mp4 Quality : 🎬 480p

27 - L3 part 1, lower respiratory tract infections, micro.mp4 Quality : 🎬 480p

26 - L1 part 3, drugs used in ttt of pulmonary infections , Pharma.mp4 Quality : 🎬 480p

25 - L1 part 2, drugs used in ttt of pulmonary infections , Pharma.mp4 Quality : 🎬 480p

24 - L3 ,The pathology of pulmonary microbial infection,patho.mp4 Quality : 🎬 480p

23 - L2 , Upper respiratory diseases (2) (Tonsil & larynx),patho.mp4 Quality : 🎬 480p

22 - L1, Upper respiratory diseases (1), Nose and pharynx, Patho..mp4 Quality : 🎬 480p

21 - L1 part1, Drug used in treatment of pulmonary infection , Pharma.mp4 Quality : 🎬 480p

20 - CBL 1, bronchial asthma, pharma.mp4 Quality : 🎬 480p